The importance of engaging all providers in tuberculosis (TB) care and prevention has been recognized for well over a decade. Over 4 million people with TB are missed each year by health systems and therefore do not get the care they need and deserve. A ...

About one third of the world’s population has latent tuberculosis (TB) infection and thus acts as a reservoir of Mycobacterium tuberculosis, the agent that causes active TB disease. More than 50 years after the first chemotherapeutic drugs for TB were introduced, the disease remains a ...

The World Health Organization (WHO) estimates that 10.4 million persons developed tuberculosis (TB) worldwide in 2016, corresponding to a global incidence of 140 TB cases per 100 000 population. Of those who developed TB, 1.0 million cases (10%) occurred among persons living with HIV. The worldwide ...

This document summarises the main outcomes of the Guidelines Development Group (GDG) meeting held in Geneva, Switzerland, from 9 to 11 November 2015 to advise the World Health Organization Global TB Programme (WHO/GTB) on the revision of the policies on drug-resistant tuberculosis treatment. This 2016 ...

Resistance to tuberculosis (TB) drugs is a formidable obstacle to effective TB care and prevention globally. Multidrug-resistant TB (MDR-TB) is multifactorial and fuelled by improper treatment of patients, poor management of supply and quality of drugs, and airborne transmission of bacteria in public places. Case ...